Evidence map›Paper›PMID 27133201›Full record

ArticleJournal of cardiac failure2016

Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials.

Justin M Vader, Shane J LaRue, Susanna R Stevens, Robert J Mentz, Adam D DeVore, Anuradha Lala, John D Groarke, Omar F AbouEzzeddine, Shannon M Dunlay, Justin L Grodin and 2 more

Open access · greenAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Journal of cardiac failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Justin M VaderWashington University School of Medicine, St. Louis, Missouri. Electronic address: jvader@dom.wustl.edu.
Shane J LaRueWashington University School of Medicine, St. Louis, Missouri.
Susanna R StevensDuke Clinical Research Institute, Durham, North Carolina.
Robert J MentzDuke Clinical Research Institute, Durham, North Carolina.
Adam D DeVoreDuke Clinical Research Institute, Durham, North Carolina.
Anuradha LalaMount Sinai Hospital, New York, New York; Brigham and Women's Hospital, Harvard University, Boston, Massachusetts.
John D GroarkeBrigham and Women's Hospital, Harvard University, Boston, Massachusetts.
Omar F AbouEzzeddineMayo Clinic, Rochester, Minnesota.
Shannon M DunlayMayo Clinic, Rochester, Minnesota.
Justin L GrodinCleveland Clinic, Cleveland, Ohio.
Victor G Dávila-RománWashington University School of Medicine, St. Louis, Missouri.
Lisa de las FuentesWashington University School of Medicine, St. Louis, Missouri.
Washington University in St. Louis · USClinical Research Institute · USBrigham and Women's Hospital · USMayo Clinic · USCleveland Clinic · US

Funding

Heart Failure Clinical Research Network Coordinating CenterU10HL084904 · NHLBI · DUKE UNIVERSITY · PI ANSTROM, KEVIN J, HERNANDEZ, ADRIAN · 2012 to 2018
$38.0M
Mayo Heart Failure Regional Clinical CenterU10HL110262 · NHLBI · MAYO CLINIC ROCHESTER · PI REDFIELD, MARGARET M · 2012 to 2018
$3.6M
Heart Failure Clinical Research Network Regional Clinical Center (U10)U10HL110312 · NHLBI · DUKE UNIVERSITY · PI FELKER, GARY M · 2012 to 2018
$3.5M
SALsalate to Improve Exercise toleraNce and LVDD in T2dm-DHF (SALIENT-DHF trial)U10HL110309 · NHLBI · WASHINGTON UNIVERSITY · PI DAVILA-ROMAN, VICTOR G., MANN, DOUGLAS L · 2012 to 2018
$3.5M
Harvard Regional Clinical Center of the NHLBI Heart Failure NetworkU10HL110337 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI GIVERTZ, MICHAEL M, LEWIS, GREGORY DYER · 2012 to 2018
$3.5M
Renal Sympathetic Denervation in Congestive Heart FailureU10HL110336 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI STARLING, RANDALL CARSON, TANG, WAI HONG WILSON · 2012 to 2018
$2.5M
Heart Failure Clinical Trials NetworkU10HL110302 · NHLBI · EMORY UNIVERSITY · PI SMITH, ANDREW · 2012 to 2018
$2.5M
Mid Atlantic Heart Failure NetworkU10HL110338 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CAPPOLA, THOMAS P., MARGULIES, KENNETH BER · 2012 to 2018
$2.4M
New England, New York and Quebec Regional Clinical CenterU10HL110342 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HUGGINS, GORDON S, VANBUREN, PETER C · 2012 to 2018
$2.3M
The Jefferson Regional Clinical Center for Heart Failure NetworkU10HL110297 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI WHELLAN, DAVID J · 2012 to 2018
$2.0M
The Texas Medical Center Regional Coordinating Center for Heart FailureU01HL084890 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI DESWAL, ANITA · 2006 to 2011
$1.8M
Gene- and Cell-based therapies for LVAD patientsU01HL084889 · NHLBI · UNIVERSITY OF UTAH · PI BULL, DAVID ANDREW · 2006 to 2011
$1.8M
NHLBI NIH HHS K23 HL116643NHLBI NIH HHS U01 HL084861NHLBI NIH HHS U01 HL084889NHLBI NIH HHS U01 HL084890NHLBI NIH HHS U01 HL084891NHLBI NIH HHS U01 HL084931NHLBI NIH HHS U10 HL084904NHLBI NIH HHS U10 HL110262NHLBI NIH HHS U10 HL110297NHLBI NIH HHS U10 HL110302NHLBI NIH HHS U10 HL110309NHLBI NIH HHS U10 HL110312NHLBI NIH HHS U10 HL110336NHLBI NIH HHS U10 HL110337NHLBI NIH HHS U10 HL110338NHLBI NIH HHS U10 HL110342
6 · The paper itself

Abstract

backgroundReadmission or death after heart failure (HF) hospitalization is a consequential and closely scrutinized outcome, but risk factors may vary by population. We characterized the risk factors for post-discharge readmission/death in subjects treated for acute heart failure (AHF). METHODS AND

resultsA post hoc analysis was performed on data from 744 subjects enrolled in 3 AHF trials conducted within the Heart Failure Network (HFN): Diuretic Optimization Strategies Evaluation in Acute Heart Failure (DOSE-AHF), Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF), and Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE-AHF). All-cause readmission/death occurred in 26% and 38% of subjects within 30 and 60 days of discharge, respectively. Non-HF cardiovascular causes of readmission were more common in the ≤30-day timeframe than in the 31-60-day timeframe (23% vs 10%, P = .016). In a Cox proportional hazards model adjusting a priori for left ventricular ejection fraction <50% and trial, the risk factors for all-cause readmission/death included: elevated baseline blood urea nitrogen, angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) non-use, lower baseline sodium, non-white race, elevated baseline bicarbonate, lower systolic blood pressure at discharge or day 7, depression, increased length of stay, and male sex.

conclusionsIn an AHF population with prominent congestion and prevalent renal dysfunction, early readmissions were more likely to be due to non-HF cardiovascular causes compared with later readmissions. The association between use of ACEI/ARB and lower all-cause readmission/death in Cox proportional hazards model suggests a role for these drugs to improve post-discharge outcomes in AHF.

Indexed as

Cause of DeathHospital MortalityAgedAngiotensin-Converting Enzyme InhibitorsDatabases, FactualDiureticsFemaleHeart FailureHospitalizationHumansLength of StayMaleMiddle AgedPatient ReadmissionPrognosisProportional Hazards ModelsAngiotensin-Converting Enzyme InhibitorsDiureticsACE inhibitorCardiorenalRAAS

Identifiers

PMID27133201
PMCPMC5085925
OpenAlexW2342753089

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.